



Advancing Health Transforming Value



1900 Lake Park Drive, Suite 380 ♦ Atlanta, GA 30080

Tel: (678) 384-7220, Fax: (678) 384-7281

www.geovax.com ♦ OTCQB: GOVX

Forward Looking Statements



Certain statements in this presentation may constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Actual results may differ materially from those included in these statements due to a variety of factors, including whether: GeoVax can develop and manufacture its vaccines with the desired characteristics in a timely manner, GeoVax's vaccines will be safe for human use, GeoVax's vaccines will effectively prevent targeted infections in humans, GeoVax's vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete vaccine development, there is development of competitive products that may be more effective or easier to use than GeoVax's products, GeoVax will be able to enter into favorable manufacturing and distribution agreements, and other factors, over which GeoVax has no control. GeoVax assumes no obligation to update these forward-looking statements, and does not intend to do so. More information about these factors is contained in GeoVax's filings with the Securities and Exchange Commission including those set forth at "Risk Factors" in GeoVax's Form 10-K.

GeoVax...Advancing Vaccines to Human Use



▶ Developing human vaccines based on

- Single-dose
- Durable immunity
- No adjuvant
- Extensive safety profile
- Cost-effective manufacturing



▶ Leveraging internal and external expertise to minimize development risk

A Compelling Opportunity



- ▶ Focused on critical unmet healthcare needs representing \$multi-billion\$ market opportunities
- ▶ Broadly validated technology & expertise
- ▶ Proof-of-concept (POC) in immuno-oncology, immuno-therapy and infectious disease indications
- ▶ Advancing high-value-potential products into clinical development
- ▶ Leadership experienced in building \$billions in incremental value


GeoVax MVA-VLP Technology & Benefits



- ▶ Combines the **recognized safety** of **MVA**
 - **MVA** (Modified Vaccinia Ankara)
 - Recognized Outstanding safety
 - Tested in 120,000 individuals, including immunocompromised, demonstrating extreme safety

- ▶ With **reproducible, durable immunogenicity** of VLPs
 - **VLP** (Virus-Like Particles)
 - VLPs are produced in the cells of the recipient (*in vivo*)
 - The protective potential of VLPs has precedent in highly immunogenic vaccines (HBV and HPV)

- ▶ **Manufacturing advantages**
 - Easy to scale-up production of the MVA vector,
 - No need to make or purify VLPs that are produced in the person being vaccinated



Advantages of GeoVax Technology



Technology	Single-Dose Immunity	Immunogenicity	Optimized VLP Formation	Transgene Stability
GeoVax MVA-VLP	Yes ✓	Excellent ✓	Yes ✓	Excellent ✓
Competitive MVA Technologies	No	Limited	No	??Unknown??

Cost-Effective Manufacturing and No Adjuvant Necessary

Broadly Validated Technology




Target Area		Indication	Preclinical	Phase 1	Phase 2
Oncology Immunotherapy		Solid Tumors	Progressing		
		Head and Neck Cancer (HPV)	Progressing		
Infectious Disease Immunotherapy		Chronic Hepatitis B	Progressing		
		HIV (functional cure)	Progressing		
Infectious Disease Prevention		Lassa Fever	Progressing		
		Ebola, Marburg, Sudan	Progressing		
		Zika Virus	Progressing		
		Malaria	Progressing		
		HIV	Progressing	Phase 1	

GeoVax Strategy to Cancer Immunotherapy


GeoVax has developed a **combination cancer vaccine strategy**:

- ▶ GeoVax novel Cancer Immunotherapy uses combinations of:
 - MVA-VLP cancer vaccines
 - Select proteins, peptides (e.g., MUC1; Cyclin B1),
 - Immune check-point inhibitors (e.g., anti-PD1)

For either **preventing or treating** solid tumors.



GeoVax Strategy to Cancer Immunotherapy



Immuno-Oncology Combination Tumor Therapy




► MUC1 Tumor Associated Antigen (TAA):

- Combination therapy:
 - MVA-VLP-MUC1 and MUC1 peptide with anti-PD1
- **GeoVax MVA-VLP combination dramatically reduces tumor**

► Indications:

- Lung, colorectal, breast, gastric, prostate, colon, pancreas, etc.




Immuno-Oncology Combination Tumor Prevention

► MUC1 Tumor Associated Antigen (TAA):

- Combination therapy:
 - MVA-VLP-MUC1 and MUC1 peptide
- **GeoVax MVA-VLP combination achieved tumor prevention**

► Indications:

- Lung, colorectal, breast, gastric, prostate, colon, pancreas, etc.



GeoVax Cancer Immunotherapy Next Steps



- ▶ **Further validate GeoVax novel cancer vaccine approach using other target antigens & novel check-point inhibitors that can be expressed by the vector and not administered separately**
- ▶ **Complete POC related to using oncolytic virus to achieve tumor cell lysis (e.g. KILLing the tumor)**
- ▶ **Proceed to clinical trials and technology validation**

GeoVax HIV Preventive Vaccine

Advancing in Human Trials



- ▶ **Excellent safety and immunogenicity: Phase 1 & 2a human clinical trials**
- ▶ **Superior antibody profile and durability compared to Sanofi Thailand Phase 3 clinical trial (RV144)**
- ▶ **Preventive vaccine: HVTN 132 – Scheduled start H2 2019**
- ▶ **Therapeutic vaccine: Phase 1 trial to begin H2-2019**
 - Collaboration with American Gene Technologies for “functional cure” effort;

GeoVax vaccine (GOVX-B11) is the most advanced vaccine candidate for the prevention of Clade B HIV (U.S. & Western Europe)



HIV VACCINE
TRIALS NETWORK

GeoVax Progressing to Significant Value Milestone



- ▶ Focus development efforts towards highest value, high likelihood areas – cancer immunotherapy
 - 1-2 development products into human trials within 12-18 months
- ▶ Secure partnership(s) for completion of clinical/regulatory activities and subsequent commercialization

Focused on Areas of Critical Healthcare Need



Hemorrhagic Fever Vaccines

- Four vaccines covering all major hemorrhagic fevers (Ebola, Sudan, Marburg, Lassa)

Zika Vaccine (GOVX-ZM01)

- A novel vaccine candidate that removes risk of ADE

HIV Vaccine (GOVX-B11)

- Most clinically advanced HIV prevention vaccine candidate for high-value commercial markets
- “Functional Cure” collaboration with American Gene Technologies International, Inc.



Immuno-Oncology Therapeutic Program

- Multiple high-value targets

Hepatitis B Virus Therapeutic Program

- Multiple vaccine antigens

Human Papilloma Virus Therapeutic Program


- Multiple vaccine antigens

Malaria Program


- Vaccine antigens covering all 3 stages of malaria infection

Hemorrhagic Fever Vaccines-Unparalleled Success

EBOLA Monkey



LASSA Normal mice



▶ **Ebola vaccine – 100% Protection, Single-Dose**

- In 2 rodent models and Nonhuman Primates
- Anticipating govt support (NIH, BARDA)

▶ **Marburg Vaccine, immunogenic in mice**

▶ **Sudan Vaccine, awaiting animal testing**

▶ **Lassa vaccine – 100% Protection, Single-Dose**

- In a lethal (intracerebral inoculation) mouse model
- Ongoing Govt. Support
 - Fast-Track Phase I / II SBIR grant from NIH
 - CDMRP grant from DoD for production of Master Seed Virus

Potential to develop a single tetravalent vaccine → Significant commercial opportunity

Zika Vaccine Program – Progressing to Clinic



► Novel vaccine design


- **Competitive Advantage**
 - No risk of Antibody Dependent Enhancement (ADE) of infection against Dengue or other flaviviruses

► Excellent preclinical data

- Immunocompetent outbred mice vaccinated IM and challenged IC (very rigorous model)
- **100% single-dose survival in vaccinated mice**
- 90-100% death in saline controls within 1 week
- Effective clearance - no virus recovered from brains of vaccinated and Zika-challenged mice

► Completed Nonhuman Primate testing with NIH grant support

(Nature's Scientific Reports 2017)



Other GeoVax Preclinical Programs



▶ Human Papilloma Virus (HPV) Vaccine (Therapeutic)

- In US: 31,500 HPV related cancers annually, >50% are head and neck cancer
- Two GeoVax MVA-VLP vaccine candidates

▶ Hepatitis B Vaccine (Therapeutic)

- Chronic Hepatitis B infection (>350M chronic carriers (globally), 1M deaths annually), current cure rates <5%
- Multiple GeoVax MVA-VLP vaccine candidates being tested

▶ Malaria Vaccine

- 214M cases and 438K deaths annually, no effective vaccine on the market
- No single correlate of immunity but rapid and strong B and T cell responses against various stages of the parasite's life cycle can be effective
- GeoVax's MVA-VLP-HIV vaccine demonstrated the characteristics of immune response needed for an effective malaria vaccine
- Multiple MVA-VLP vaccine candidates being evaluated



Strong IP Protection



► Patent Portfolio

- Owner of Record Patents
 - U.S. – 11 applications pending
 - Non-U.S. – 17 application pending
- Licensed Patents
 - U.S. – 10 issued, 2 applications pending
 - Non-U.S. – 14 issued, 2 applications pending



GeoVax Value → Proprietary Expertise in Vaccine Vector Development

Management Team – Experience & Expertise



David A. Dodd
Chairman, President & CEO



Mark W. Reynolds, CPA
Chief Financial Officer



Farshad Guirakhoo, PhD
Chief Scientific Officer



Harriet L. Robinson, PhD
Chief Scientific Officer, Emeritus





Board of Directors and Scientific Advisors

Board of Directors

David Dodd (Chairman, President & CEO)

- Abbott, Bristol-Myers Squibb, Serologicals, Solvay, Wyeth

Randal Chase, PhD

- Bristol-Myers, Connaught, Glaxo, North American Vaccine, Pasteur Merieux, Shire

Dean Kollintzas

- Patent Attorney – Biopharma, FDA

Robert McNally, PhD

- Retired GeoVax President/CEO
- Founder, Cell Dynamics; Co-Founder, CryoLife

Harriet Robinson, PhD

- Professor, University of Massachusetts Medical Center
- Emory Vaccine Center; Professor, Emory University
- GeoVax Co-founder & CSO Emeritus

Jack Spencer

- Ernst & Young – Life Sciences

Scientific Advisory Board

Thomas Monath, MD (Chairman)

- Managing Director & CSO, Crozet BioPharma
- Acambis, Hookipa, PaxVax, NewLink Genetics, PerkinElmer

Olja Finn, PhD

- Prof. Immunology and Surgery, Univ. of Pittsburgh

Barney Graham, MD, PhD

- Sr. Investigator, VRC, NIAID/NIH

Stanley Plotkin, MD

- Vaxconsult, LLC
- Sanofi Pasteur

Scott Weaver, PhD

- Director UTMB Inst. for Human Infections and Immunity

A Compelling Opportunity



- ✓ **Developing novel, patented vaccines and immunotherapies based on a unique technology & expertise**
 - ❖ **Robust, durable immunity, single-dose, no adjuvant, cost-effective manufacturing, safe vaccines**
- ✓ **Focused on critical major medical needs with differentiated advantages**
- ✓ **Translational programs underway to pursue clinical and regulatory development**





Advancing Health Transforming Value



1900 Lake Park Drive, Suite 380 ♦ Atlanta, GA 30080

Tel: (678) 384-7220, Fax: (678) 384-7281

www.geovax.com ♦ OTCQB: GOVX